Natural Killer Cell-Based Immunotherapy against Glioblastoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032111 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Takayuki Morimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: a Grand-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan.
- Department of Neurosurgery, Nara City Hospital, Nara 630-8305, Japan.
- Grandsoul Research Institute for Immunology, Inc., Uda 633-2221, Japan.
- Clinic Grandsoul Nara, Uda 633-2221, Japan.
ORCID-Profile: Takayuki Morimoto, Tsutomu Nakazawa, Ichiro Nakagawa, Ryosuke Matsuda
Förderung
- a Grand-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan
Zitieren
APA
Morimoto, T., Nakazawa, T., Maeoka, R., Nakagawa, I., Tsujimura, T., & Matsuda, R. (2023). Natural Killer Cell-Based Immunotherapy against Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032111
Vancouver
Morimoto T, Nakazawa T, Maeoka R, Nakagawa I, Tsujimura T, Matsuda R. Natural Killer Cell-Based Immunotherapy against Glioblastoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032111
BibTeX
@article{Morimoto2023,
author = {Morimoto, Takayuki and Nakazawa, Tsutomu and Maeoka, Ryosuke and Nakagawa, Ichiro and Tsujimura, Takahiro and Matsuda, Ryosuke},
title = {Natural Killer Cell-Based Immunotherapy against Glioblastoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032111}
}
EUVIMED